Sanofi has entered into a strategic partnership with Cheplapharm, transferring 20 mature medicines and three manufacturing sites worldwide to the Swiss generic drugmaker in exchange for a 26.4% equity stake.

The deal, announced on September 14, 2026, builds on a collaboration that began in 2014. Sanofi will receive the equity stake as consideration for the asset transfer, marking a shift in its portfolio strategy to focus on innovation while retaining ownership interest in the acquiring entity.

Deal Structure

The transaction involves the handover of specific product lines and operational facilities. Key components include:

• Transfer of 20 mature medicine brands to Cheplapharm.
• Handover of three global manufacturing sites.
• Sanofi acquisition of a 26.4% equity stake in Cheplapharm.

Manufacturing Sites and Timeline

Three manufacturing sites will be transferred to Cheplapharm: Csanyikvölgy in Hungary (c.400 employees), Jurong in Singapore (c.100 employees), and Ploërmel in France (c.65 employees). Existing employment arrangements and collective agreements will be maintained.

The commercial transfer of the medicine portfolio is planned to begin in the first quarter of 2027. The site transfer will follow, subject to employee consultation procedures, regulatory approvals, and customary closing conditions. The transaction is expected to be fully completed by the third quarter of 2027.

Strategic Implications

The partnership reflects a shared conviction that innovative medicines and mature medicines require different operating models tailored to their specific manufacturing, regulatory, and commercial needs. Cheplapharm’s specialized expertise will ensure these medicines continue to meet patient needs throughout their lifecycle.

By converting asset value into an equity stake, Sanofi maintains exposure to the future performance of these mature products without bearing direct operational costs. The retention of a quarter-plus stake suggests confidence in the long-term cash flow potential of the transferred portfolio under Cheplapharm’s management.

Key Products and Financial Impact

The medicines being divested include Lovenox/Clexane (enoxaparin), excluding the US market. Cheplapharm Co-CEOs Edeltraud Lafer and Sebastian Braun noted that the project incorporates products complementing their extensive portfolio, including the expertise required to produce the flagship product Lovenox/Clexane.

Sanofi stated that the proposed transaction is not expected to have any impact on its financial guidance for 2026. Additional financial details are expected to be provided at a later stage.

The Supreme Court dismissed Sanofi 's petition seeking to quash criminal proceedings related to pharmaceutical supplies made to the Bhabha Atomic Research Centre (BARC) between 2012 and 2015. The order, dated September 7, 2026, addresses the maintainability of prosecution against the company even without individual employee arraignment.

The apex court did not record any finding of guilt nor adjudicate on the merits of the case. The Central Bureau of Investigation (CBI) complaint alleges conspiracy with a BARC personnel to wrongfully influence procurement decisions. The criminal complaint remains pending for trial.

Legal Context

Sanofi India Limited disclosed the development under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company received the order on September 7, 2026, and filed the disclosure with stock exchanges on September 8, 2026.

Operational Impact

Sanofi stated it is assessing the judgment and formulating its next litigation strategy. The company confirmed that the judgment does not impose any penalty, conviction, or operational restriction at this stage. The matter involves allegations regarding supplies to BARC in Mysore during the 2012-2015 period.